Renal Artery Stenting in Patients With Documented Resistant Hypertension and Atherosclerotic Renal Artery Stenosis (ANDORRA)

Inclusion Criteria: * Age: 40 to 80 Years * Men or women * Supine office BP ≥ 140 and/or 90 mmHg at screening despite a stable medication regimen including full tolerated doses of 3 or more anti-hypertensive treatments of different classes, including a diuretic. * Unilateral or bilateral ARAS of a main renal artery ≥60% diagnosed by renal CT- angiogram (or MR-angiogram if there is a contraindication to perform CT) performed in the year before * One or two functional kidney(s) ≥ 70 mm in pole-to-pole length * eGFR ≥ 20 ml/min/1.73 m² (MDRD formula) * Signed informed consent * Social insurance coverage Inclusion criteria for the renal angiogram procedure: \- RH confirmed by daytime ABPM ≥ 135 or 85 mmHg after 1 month treatment with SOMT at Visit V1. Inclusion criteria for the randomization: * Unilateral or bilateral ARAS of a main renal artery ≥ 60% confirmed on renal angiogram by Quantitative Vascular Analysis (QVA) * Increase in plasma creatinine \< 30% after 4-week SOMT Exclusion Criteria: * Fibromuscular dysplasia of renal artery or other non-atherosclerotic renal artery stenosis * Other secondary form of hypertension excluded on the basis of a clinical, hormonological and/or imaging work-up * Restenosis after a previous renal angioplasty or stenting * Only a stenosis of an accessory renal artery supplying \<1/2 of the ipsilateral renal parenchyma * Additional indication of ARAS stenting (Malignant hypertension, ≥ 30% increase in plasma creatinine after renin angiotensin system (RAS) blocker or after RAS blocker and diuretic administration, flash pulmonary edema) * Kidney pole-to-pole length \< 70 mm * Vascular disease precluding access for stenting * Abrupt vessel closure or dissection after diagnostic angiography * Contraindication to renal artery stenting according the notice for use of the stents * eGFR \< 20 ml/min/1.73 m² (MDRD) * History of transient ischemic accident (TIA) or cerebrovascular accident (CVA) during the 3 months prior to visit 1 * History of acute heart failure or heart failure (NYHA class III-IV) within the 3 months prior to visit 1 * History of myocardial infarction, unstable angina, coronary bypass or percutaneous coronary angioplasty during the 3 months prior to visit 1 * Abdominal aortic aneurysm with indication for surgery or EVAR (Endovascular Aneurysm Repair) * Known history of cholesterol embolism * Brachial circumference of ≥ 42 cm * Severe contrast media allergy, not amenable to pre-treatment * Allergy to aspirin or clopidogrel * Atrial fibrillation * Comorbid condition causing life expectancy ≤ 3 years * Unlikely to co-operate in the study and/or poor compliance anticipated by the investigator * Participant not affiliated to the French social security * Pregnancy or breastfeeding * Guardianship for incapacity